Volume | 8,702 |
|
|||||
News | - | ||||||
Day High | 3.71 | Low High |
|||||
Day Low | 3.30 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
GT Biopharma Inc | GTBP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.71 | 3.30 | 3.71 | 3.7516 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
89 | 8,702 | $ 3.42 | $ 29,772 | - | 3.2125 - 16.11 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:13:44 | 20 | $ 3.3524 | USD |
GT Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.56M | 1.38M | - | 0 | -7.6M | -5.50 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GT Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GTBP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.80 | 3.88 | 3.2125 | 3.69 | 4,717 | -0.50 | -13.16% |
1 Month | 4.58 | 4.77 | 3.2125 | 4.03 | 6,931 | -1.28 | -27.95% |
3 Months | 5.538 | 6.00 | 3.2125 | 4.80 | 19,203 | -2.24 | -40.41% |
6 Months | 7.35 | 9.90 | 3.2125 | 6.88 | 86,270 | -4.05 | -55.10% |
1 Year | 10.50 | 16.11 | 3.2125 | 8.62 | 227,295 | -7.20 | -68.57% |
3 Years | 345.90 | 591.993 | 3.2125 | 140.34 | 215,904 | -342.60 | -99.05% |
5 Years | 165.00 | 591.993 | 3.2125 | 154.35 | 245,191 | -161.70 | -98.00% |
GT Biopharma Description
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. |